Nuvectis Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for serious diseases. Its pipeline includes kinase inhibitors aimed at advanced solid tumors and a complement Factor B inhibitor for conditions driven by dysregulated complement activity. The company focuses on precision approaches where targeted pathway blockade may address high unmet medical need.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -6.3 | — |
| Q3 2025 | 0 | — | -9.9 | — |
| Q4 2025 | 0 | — | -7.3 | — |
| Q1 2026 | 0 | — | -6 | — |
| Q2 2026 | 0 | — | -7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Enovix Corporation (ENVX), Bowman Consulting Group Ltd. (BWMN), WhiteFiber, Inc. (WYFI), CytomX Therapeutics, Inc. (CTMX), Neurogene Inc. (NGNE), Scholastic Corporation (SCHL)